SGLT2 inhibitors - Important Safety Information from Janssen-Cilag, AstraZeneca Ltd. and Boehringer Ingelheim Ltd. as approved by the HPRA

Notice type: 3rd Party Publications

Date: 14/07/2015

Important Safety Information communication from Janssen-Cilag Limited, AstraZeneca Ltd. and Boehringer Ingelheim Ltd. on the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors - INVOKANA (canagliflozin), VOKANAMET(canagliflozin/metformin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin), SYNJARDY (empagliflozin/metformin).

Important Safety Information - SGLT2 inhibitors